Top News

FUJIFILM Diosynth Biotechnologies to Create Major Biopharma Manufacturing Site in United Kingdom

December 16, 2021

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

Pfizer Acquires Arena Pharmaceuticals for $6.7 Billion

December 15, 2021

Pfizer’s $6.7 billion acquisition of Arena will give them access to a portfolio of immuno-inflammatory therapies.

Pfizer and BioNTech Provide Update on Omicron Variant

December 09, 2021

Pfizer found that two-dose recipients exhibited a more than 25-fold reduction in neutralization titers against Omicron relative to wild-type.

AstraZeneca Signs Blockbuster Deal With Ionis for TTR Amyloidosis Treatment

December 08, 2021

AstraZeneca struck a deal worth up to more than $3.5 billion with Ionis Pharmaceuticals for the rights to develop and commercialize their transthyretin (TTR) amyloidosis treatment.

Recordati Acquires EUSA Pharma for $845 Million

December 06, 2021

Recordati’s blockbuster acquisition of EUSA Pharma gives them access to a portfolio of four drugs that treat rare cancers.

EMA Recommends Pfizer and BioNTech’s COVID-19 Vaccine for Children

November 29, 2021

The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.

FDA Authorizes COVID-19 Boosters for All Adults

November 19, 2021

FDA has amended its EUA for Pfizer-BioNTech’s and Moderna’s COVID-19 booster to include all individuals aged 18 or older.

Novo Nordisk Acquires Dicerna for $3.3 Billion

November 19, 2021

Novo Nordisk’s 3.3 billion acquisition of Dicerna gives them access to their RNAi technology.

Pfizer Submits COVID-19 Oral Antiviral Candidate to FDA for Emergency Use Authorization

November 17, 2021

Pfizer’s PAXLOVID oral solid-dosage treatment is designed to combat SARS-CoV-2 in high-risk patients at the first sign of infection.

Califf Named to Head FDA

November 12, 2021

The White House has nominated Robert Califf to head FDA, ending months of uncertainty about the future path for the high-profile agency.